Jiangsu Hengrui Medicine Co., Ltd.

600276.SS

54.5

CNY

-1.10

(-1.98%)

Day's range

54.3

52 wk Range

37.24

57.53

General Financials Dividends Technical

Key Statistics

Previous Close

55.6

Open

55.9

Day's Range

54.3 - 56

52 wk Range

37.24 - 57.53

Volume

54.18M

Average Volume

49.19M

Market Cap

346.05B

Shares Outstanding

6.35B

Revenue

27.98B

Net Income

6.34B

EPS

1.09

P/E Value

Next Earnings Date

Aug 20, 2025

Dividend (Yield)

0.73%

Return on Assets

13.34%

Return on Equity

15.30%

Gross Profit Margin

86.06%

Price/Book

7.25

EBITDA

7.95B

EV/EBITDA (TTM)

40.22

P/BV Value

7.25

P/S Value

11.88

Beta

0.445

Jiangsu Hengrui Medicine Co., Ltd. Company Profile

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.

Industry

Drug Manufacturers - General

Sector

Healthcare

Employes

20238

Market

Site

https://hrs.com.cn